pentoxifylline tablet film coated extended release
cardinal health - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline 400 mg
pentoxifylline tablet film coated extended release
cardinal health - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline 400 mg
pentoxifylline tablet extended release
avkare, inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline 400 mg
nu-pentoxifylline-sr 400 mg tablet (extended-release)
nu-pharm inc - pentoxifylline - tablet (extended-release) - 400mg - pentoxifylline 400mg - hemorrheologic agents
pentoxifylline tablet film coated extended release
mckesson contract packaging - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline 400 mg
pentoxifylline 200mg/5ml oral solution
special order - pentoxifylline - oral solution - 40mg/1ml
pentoxifylline 100mg/5ml oral solution
special order - pentoxifylline - oral solution - 20mg/1ml
pentoxifylline 100mg/5ml oral suspension
special order - pentoxifylline - oral suspension - 20mg/1ml
pentoxifylline tablet, extended release
ani pharmaceuticals, inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline extended-release tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline extended-release tablets should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
trental 400 pentoxifylline (oxpentifylline) 400 mg modified release tablet blister pack
clinect pty ltd - pentoxifylline, quantity: 400 mg - tablet, modified release - excipient ingredients: povidone; hyetellose; titanium dioxide; hypromellose; erythrosine; purified talc; macrogol 8000; magnesium stearate - treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. trental 400 can thus improve function and symptoms but is not intended to replace more definitive therapy, such as vascular surgery, or removal of arterial obstructions when treating peripheral vascular disease.